source
- Windward Bio raises $225 million in IPO to fund Chinese-sourced respiratory drug programWindward Bio, backed by Sanofi, completed its initial public offering at the $225 million target, selling 10.3 million shares at $17 each. The proceeds will be used to advance two respiratory drug…
- Argenx CEO Karen Massey drives $3.4 billion of acquisitions to expand beyond VyvgartArgenx, a rare‑disease biotech, announced that under its new CEO Karen Massey it has pursued two acquisitions. The deals together have a potential value of about $3.4 billion and are intended to b…